Provexis Raises Funds for Growth

BERKSHIRE, EnglandProvexis plc announced it has raised significant funds to allow the company to accelerate its strategy of developing new functional and medical food ingredients and dietary supplement technologies.

Provexis recruitment of three R&D and formulation scientists adds further depth and knowledge to the experienced management and scientific teams based at the University of Liverpool and the University of Aberdeens Rowett Institute of Nutrition and Health.

The company reported its technology continues to strengthen with the extension of the Crohns disease trial into two new centers in Edinburgh and Bristol. This move will facilitate a successful conclusion to the trials in 2011 and partnered technology commercialization. Two further clinical trials will start in early 2011; with the University of Liverpool on hospital superbug Clostridium difficile and with the Institute of Food Research for reduction of cardiovascular inflammation using novel plant-derived extracts.

 Our self-contained business platform spans IP creation and R&D through to clinical trials, commercialization and regulatory approval," commented Stephen Moon, chief executive. This makes us an attractive collaborative partner for companies seeking growth in the supplements, functional and medical food markets. Were actively seeking new technologies to acquire and continue to screen a range of possible opportunities."